NRx Pharmaceuticals Establishes $20 Million ATM Stock Program

NRX Pharmaceuticals ( (NRXP) ) just unveiled an announcement.

On February 17, 2026, NRx Pharmaceuticals filed a prospectus supplement covering up to $20 million of its common stock under an existing at-the-market offering agreement with H.C. Wainwright & Co., with shares to be issued pursuant to an effective shelf registration on Form S-3 and related base prospectus. The company also filed a Current Report on Form 8-K to furnish a legal opinion from Cozen O’Connor on the validity of the shares to be issued, a procedural step that underpins the regulatory compliance of its planned equity sales and supports its ongoing access to capital markets.

These actions formalize the framework under which NRx can sell additional common stock into the market over time, potentially affecting its capital structure and dilution profile for existing shareholders. The filings indicate that NRx is maintaining the legal and disclosure infrastructure necessary to execute at-the-market offerings efficiently, which may influence its financial flexibility and investor perceptions of its funding strategy.

The most recent analyst rating on (NRXP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.

Spark’s Take on NRXP Stock

According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.

The score is held down primarily by weak financial performance (large losses, ongoing cash burn, and negative equity) and bearish technicals (price below key moving averages with negative MACD). This is partially offset by a more positive earnings-call outlook tied to initial revenue generation, clinic expansion plans, and drug-approval progress, while valuation is difficult to assess due to negative earnings and no provided dividend yield.

To see Spark’s full report on NRXP stock, click here.

More about NRX Pharmaceuticals

NRx Pharmaceuticals, Inc. is a biotechnology company operating in the pharmaceutical sector, listed as an Inc. and engaged in the issuance of common stock as part of its capital markets activities. The company utilizes at-the-market equity offerings to access public capital, reflecting an ongoing strategy of financing its operations through registered securities issuances.

Average Trading Volume: 924,385

Technical Sentiment Signal: Sell

Current Market Cap: $53.29M

For detailed information about NRXP stock, go to TipRanks’ Stock Analysis page.